CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY

Yazmin Odia; Ludimila Cavalcante; Howard Safran; Steven Francis Powell; Pamela Munster; Wen Wee; Benedito Carneiro; Bruno Bastos; Francis Giles; Solmaz Sahebjam

doi:10.1093/NEUONC/NOAB196.238

CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY

Yazmin Odia, Ludimila Cavalcante, Howard Safran, Steven Francis Powell, Pamela Munster, Wen Wee, Benedito Carneiro, Bruno Bastos, Francis Giles, Solmaz Sahebjam

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	23
DOIs	https://doi.org/10.1093/NEUONC/NOAB196.238
State	Published - Nov 12 2021

Disciplines

Oncology

Access to Document

10.1093/NEUONC/NOAB196.238License: Unspecified

Cite this

Odia, Y., Cavalcante, L., Safran, H., Powell, S. F., Munster, P., Wee, W., Carneiro, B., Bastos, B., Giles, F., & Sahebjam, S. (2021). CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY. Neuro-oncology, 23. https://doi.org/10.1093/NEUONC/NOAB196.238

Odia, Y, Cavalcante, L, Safran, H, Powell, SF, Munster, P, Wee, W, Carneiro, B, Bastos, B, Giles, F & Sahebjam, S 2021, 'CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY', Neuro-oncology, vol. 23. https://doi.org/10.1093/NEUONC/NOAB196.238

@article{c48352527bc646b980db53a158ef928d,

title = "CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY",

author = "Yazmin Odia and Ludimila Cavalcante and Howard Safran and Powell, {Steven Francis} and Pamela Munster and Wen Wee and Benedito Carneiro and Bruno Bastos and Francis Giles and Solmaz Sahebjam",

note = "You do not currently have access to this article. Subscription prices and ordering for this journal Don't already have an Oxford Academic account? Register CTNI-13.",

year = "2021",

month = nov,

day = "12",

doi = "10.1093/NEUONC/NOAB196.238",

language = "American English",

volume = "23",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY

AU - Odia, Yazmin

AU - Cavalcante, Ludimila

AU - Safran, Howard

AU - Powell, Steven Francis

AU - Munster, Pamela

AU - Wee, Wen

AU - Carneiro, Benedito

AU - Bastos, Bruno

AU - Giles, Francis

AU - Sahebjam, Solmaz

N1 - You do not currently have access to this article. Subscription prices and ordering for this journal Don't already have an Oxford Academic account? Register CTNI-13.

PY - 2021/11/12

Y1 - 2021/11/12

UR - https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi61/6426522

U2 - 10.1093/NEUONC/NOAB196.238

DO - 10.1093/NEUONC/NOAB196.238

M3 - Article

VL - 23

JO - Neuro-oncology

JF - Neuro-oncology

ER -

CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY

Disciplines

Access to Document

Other files and links

Cite this